HOME >> BIOLOGY >> NEWS
First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely

The first rigorous study of the dietary supplement resveratrol found that oral dietary supplements of resveratrol are unlikely to have any effect on breast and prostate cancer.

Dr. Thomas Walle, Medical University of South Carolina, presented the results at Experimental Biology 2004, as part of the scientific sessions of the American Society of Pharmacology and Experimental Therapeutics.

Resveratrol, a plant antioxidant found in abundance in grapes, wine, and peanuts, is widely sold as a dietary supplement with claims of numerous beneficial health effects. These range from extending life spans to preventing heart disease and cancer. However, these positive health effects have mainly been shown in cultured cells, and it has been unclear if resveratrol can reach the circulating blood in sufficient amounts to have therapeutic effects.

In the study by Dr. Walle and research associate Kristina Walle, C-14-Tagged resveratrol was administered both by mouth and intravenously to healthy volunteers. The researchers found that resveratrol (25-mg doses) is very well absorbed after oral dosing with most of the dose appearing in the urine in the first 12 hours. However, the urine contained resveratrol only as sulfate and glucuronic acid conjugates, none as the free, presumably active, form.

Likewise, the only blood samples containing free resveratrol were those drawn within 30 minutes after the intravenous injection. No free resveratrol was present in blood samples drawn after oral doses.

Based on this study's findings, Dr. Walle ways it would seem highly unlikely that resveratrol per se can have any effect on cardiovascular disease or cancer of such organs as the breast or prostate gland when consumed in the diet or as a dietary supplement.

However, he adds, it is still possible that orally administered resveratrol can prevent cancers along the aerodigestive tract. It is also possible that a resveratrol sulfate conjugate detected
'"/>

Contact: Sarah Goodwin
eb4press@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
19-Apr-2004


Page: 1 2

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2018)... ... December 21, 2018 , ... ... and hosted the Boston Healthcare Drinks event featuring Helen Chen, Greater China Managing ... China.” , The discussion was moderated by patent attorney David J. Dykeman ...
(Date:12/19/2018)... (PRWEB) , ... December 19, 2018 , ... InTouchMD’s flagship ... innovative products in healthcare for 2018. , PM360 is featuring the recognition in ... products and services offered to the pharmaceutical and medical device industries. , “This ...
(Date:12/18/2018)... ... December 18, 2018 , ... ... cancers and other serious diseases, today announced the publication of an early feasibility ... treatment of rGBM. , The publication of the study, An Early Feasibility ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today announced ... candidate, code-named "KM-819." KM-819 is an orally active small molecule that is ... Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to ...
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection and desire to improve ... the European Union (EU) on the horizon, Jim Kasic, president and CEO of Boulder ... the EU Medical Device Regulation (MDR), digital health, and big data are just a ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
Breaking Biology Technology:
Cached News: